Disclosure of Interest Declarations - TEAP Medical Technical Options Committee (MTOC) - As of April 2009

Emmanuel Addo-Yobo, Ghana (A5)
Emmanuel Addo-Yobo, member of the Medical Technical Options Committee since 2005, is a full time Senior Specialist Paediatrician and Senior Lecturer in the Department of Child Health, Kwame Nkrumah University Sciences and Technology, and the Komfo Anokye Teaching Hospital, Kumasi, Ghana, with a special interest in paediatric pulmonology. Dr Addo-Yobo is the physician in charge of paediatric asthma in the hospital and has been involved in several research activities on childhood asthma epidemiology in Ghana as Principal or Co-Investigator, some of which have been sponsored partly or fully by pharmaceutical companies. Dr Addo-Yobo has attended an American Academy of Allergy Asthma and Immunology (AAAAI) meeting sponsored by a pharmaceutical company in 1999.  Dr Addo-Yobo does not receive any form of remuneration from any drug companies. Dr Addo-Yobo has given educational lectures to medical personnel on childhood asthma in Ghana which were sponsored by drug companies in a purely academic capacity. The UNEP’s Ozone Secretariat funds his travels for MTOC meetings. Dr Addo-Yobo’s spouse is a business secretary work ing with a local financial institution and has no interests in matters before the Protocol.

Paul J.Atkins, USA (Non-A5)
Dr Paul Atkins, member of the Medical Technical Options Committee since 1993, is the full time President and Chief Operating Officer of Oriel Therapeutics Inc, a privately held pulmonary drug delivery company based in Research Triangle Park, USA. Oriel Therapeutics Inc. has an interest in the topics of the Montreal Protocol because it is developing dry powder inhalers. Dr Atkins has a proprietary interest in developing alternatives to ODS-based MDIs and owns stock in Oriel Therapeutics, Inc. Dr Atkins has an extensive background in both MDI and DPI product development and commercialisation and is an internationally recognised expert in this area. Previously Dr Atkins was employed by GlaxoSmithKline, a leading provider of inhaled medicines including CFC based MDIs, and his spouse is currently a GlaxoSmithKline employee and owns stock in that company. Dr Atkins has worked occasionally as a consultant for both MLF and UNDP on matters related to the Montreal Protocol. Travel to MTOC meetings has been paid by either his employer or out of his personal funds.

Sidney Stuart Braman, USA (Non-A5)
Dr Sidney Braman, member of the Medical Technical Options Committee since 2005, is a Professor of Medicine at Brown Medical School and Director of the Division of Pulmonary and Critical Care Medicine at Brown University and the Rhode Island Hospital. These organizations have no direct interest or business relating to the topics of the Montreal Protocol. Dr Braman has no proprietary interest to alternatives or substitutes to ODS, does not own stock in companies producing ODS or alternatives or substitutes to ODS, does not have an interest in the outcome of essential use nominations and does consulting for organizations seeking to phase out ODS but does not consult on these products. He has received research grant support and been a consultant to several pharmaceutical companies relating to research on new drug development. Dr Braman has not received any consultancy fees for work related to or associated with the Montreal Protocol. Dr Braman’s spouse has no interest in matters before the Protocol. Dr Braman does not work as a consultant on matters relates to the Montreal Protocol. Travel to the MTOC meetings is provided by the American Thoracic Society.

Nick Campbell, France (Non-A5)
Dr. Nick Campbell has been a member of this Technical Options Committee since 1991. Dr Campbell has spent 20 years working primarily on the ozone layer issue and climate change. Dr Campbell works for ARKEMA SA, based in Paris, as the Environment Manager for the Fluorinated Products Division. ARKEMA SA is a producer of CFCs, HCFCs and HFCs. ARKEMA SA supports his participation and travel on MTOC. Dr Campbell has stock options in ARKEMA SA. He is Chairman of the European Fluorocarbon Technical Committee (EFCTC) that represents the producers of fluorocarbons in the European Union and the European Chemical Industry Council (CEFIC) Working Party on Climate Change. Dr Campbell is also the Chairman of the International Chamber of Commerce (ICC) Working Party on Climate Change and the Chairman of the BusinessEurope Climate Change Working group, representing European Union Employers’ federations. Dr Campbell has been a member of the World Bank’s Ozone Operations Resource Group. Nick was a Coordinating Lead Author for the IPCC/TEAP joint Report on HFCs and PFCs (April, 2005). Dr Campbell was awarded a 1997 United States EPA Stratospheric Ozone Protection Award for his role in the phase-out of ODS.

Hisbello Campos, Brazil (A5)
Dr. Hisbello S. Campos, member of the Medical Technical Options Committee since 1997, is a medical physician (pulmonologist) who works for Brazil´s Ministry of Health at Centro de Referencia Prof. Helio Fraga. Dr Campos is a full time physician at the Centro de Referencia Prof. Helio Fraga and gives medical consultations at his private office. The Centro de Referencia Prof. Helio Fraga has an interest in the topics of the Montreal Protocol because it is the government department responsible for proposing guidelines for respiratory diseases control. Dr Campos has no proprietary interest in alternatives or substitutes to ODS, does not own stock in companies producing ODS or alternatives or substitutes to ODS, does not have an interest in the outcome of essential use nominations, and does not consult for organizations seeking to phase out ODS. Dr. Campos gives educational lectures for physicians or goes to international medical meetings (American Thoracic Society, European Respiratory Society or World Asthma Meeting, for example), sponsored by pharmaceutical companies, some of which have continued to produce CFC MDIs, and some of which have sought to accelerate phase out of CFC MDIs. Dr Campos’s spouse has no interest in matters before the Protocol. Dr Campos works occasionally as a consultant to the Brazilian Government on matters related to the Montreal Protocol. Dr. Hisbello Campos’ spouse has no interest in matters before the Protocol. Travel to TOC meetings is paid by UNEP’s Ozone Secretariat.

Jorge Osvaldo Cáneva, Argentina (A5)
Dr. Jorge Osvaldo Cáneva, member of the Medical Technical Options Committee since 2007, is the Chief of the Pulmonary Section at of the University Hospital of the Favaloro Foundation (Buenos Aires, Argentina) since it was established in 1992, and Professor of the University School of Medicine at the same institution. Currently Dr. Cáneva states as Ex-President of the Argentine Association of Respiratory Medicine (Asociación Argentina de Medicina Respiratoria), main association in pulmonary medicine in Argentina. Currently Dr. Cáneva is Governor of the American College of Chest Physician in Argentina. He is the coordinator of the Bi-National Programme for pulmonary and cardiopulmonary transplantation between Argentina and Uruguay. He has been involved in severe respiratory diseases, pulmonary vascular diseases and lung transplantation programmes. During 2003 and 2004 Dr Cáneva has been involved in consultation for AstraZeneca Argentina about dry powder inhalers. Between 1993 and 2008, Dr Cáneva has served as independent consultant on long-term oxygen therapy for Air Liquide Argentina. Furthermore, he serves as independent consultant about inhaled (nebulized) therapy for the treatment of pulmonary vascular diseases. While he was not directly involved in preparing the Essential Use Nomination of Argentina, Dr Cáneva responded to a request of the Government of Argentina to review the structure of the document and was consulted after January 31st (deadline for the submission of the nomination) about some points and statistics and provided some advice. As a consequence, during the 2009 MTOC meeting Dr Cáneva abstained from participation in decisions regarding Argentina’s essential use nomination. Dr Cáneva does not own stock in companies producing ODS or alternatives or substitutes to ODS; he does not consult for organizations seeking to phase out ODS. Dr Cáneva’s spouse has no relationship with any pharmaceutical company. He does not receive any honorarium or grant from the government, national or international non-profit organization. Travel to MTOC meetings is paid by UNEP’s Ozone Secretariat.

Christer Carling, Sweden (Non-A5)
Christer Carling, member of the Medical Technical Options Committee since 1993, is retired from a position as Director Global Licensing at the pharmaceutical company AstraZeneca, which is developing and supplies inhalable drugs such as DPIs and MDIs for the treatment of asthma and COPD. Mr Carling is at present an independent consultant in the pharmaceutical area. His ongoing consultancy activities do not involve services to any organization with an interest in the topics of the Montreal Protocol. Mr Carling is a minor shareholder in AstraZeneca but has no proprietary interest in substitutes to ODS, does not own stock in companies producing ODS or substitutes to ODS, does not have an interest in the outcome of essential use nominations, and does not consult for organizations seeking to phase out ODS. During 2008 and 2009 Mr Carling participated in regional UNEP seminars in Latin America and South Asia, presenting on aspects of the Essential Use Nomination (EUN) process and assisting individual Article 5 Parties in the South Asia region in their EUN preparations. As a consequence, during the 2009 MTOC meeting Mr Carling abstained from participation in decisions regarding the EUNs from Bangladesh, China, India, Iran and Pakistan. His spouse is currently an AstraZeneca employee but has no direct interest in matters before the Protocol. Mr Carling’s travel to MTOC meetings is paid entirely out of his own pocket

Gui-liang Chen, China (A5)
Dr Gui-liang Chen, member of the Medical Technical Options Committee since 2008, is a chief pharmacist, and a full time researcher at the Shanghai Institute for Food and Drug Control (SIFDC). The SIFDC has an interest in the topics of the Montreal Protocol because it is an official institute for drug quality control in China. Gui-liang Chen has been engaged in assessing the safety, efficacy and quality of inhalation products since 2002. Gui-liang Chen has no proprietary interest in alternatives or substitutes to ODSs, does not own stock in companies producing ODS or alternatives or substitutes to ODSs, and does not consult for organizations seeking to phase-out ODSs. Gui-liang Chen’s spouse works at a local hospital in Shanghai, and has no interest in matters before the Protocol. Dr Chen works occasionally as a consultant to the China Government on matters related to the Montreal Protocol. Travel to MTOC meetings is paid by UNEP’s Ozone Secretariat.

Antoine Haddad, Italy (Non-A5)
Antoine Haddad, member of the Medical Technical Options Committee since 2007, is a full time Area Manager Middle East at Chiesi Farmaceutici S.p.A. located in Parma, Italy. Mr Haddad has significant experience with more than 20 years of activity in the specific field, in licensing, technology and know-how transfer, for local production in many Middle East countries.  Chiesi Farmaceutici S.p.A. has an interest in the topics of the Montreal Protocol as a producer and licensor of MDIs, including Egypt, Iran and Syria and have proprietary interest in alternatives or substitutes to ODS, and an interest in the outcome of the Egypt, Iran and Syria essential use nominations made in 2009. As a consequence, during the 2009 MTOC meeting Mr. Haddad abstained from participation in decision-making regarding the essential use nominations from Egypt, Iran and Syria. Mr Haddad does not own stock in companies producing ODS or alternatives or substitutes to ODS, and does not consult for organizations seeking to phase out ODS. Mr Haddad’s family members and parents have no direct or indirect interest in matters relative to the Protocol. He does not work as a consultant on matters related to the Montreal Protocol. Travel to MTOC meetings is paid by Chiesi Farmaceutici S.p.A., which do not receive contributions for this travel.

Charles Hancock, USA (Non-A5)
Charles O. Hancock, is a private medical device sterilization consultant with Charles O. Hancock Associates, Inc. Mr Hancock has an interest in the topics of the Montreal Protocol because he is actively engaged in the safe and effective delivery of sterilization processes for medical devices in healthcare applications. Mr Hancock has proprietary interest in alternatives or substitutes to ODS, owns stock in a company producing alternatives or substitutes to ODS, does not have an interest in the outcome of essential use nominations, and does provide consulting for organizations seeking to phase out ODS. Mr Hancock’s spouse has no interest in matters before the Protocol. Mr Hancock works frequently as a consultant to governments, companies, and healthcare institutions on matters related to the Montreal Protocol. Travel to MTOC meetings is paid by Mr Hancock.

Eamonn Hoxey, UK (Non-A5)
Dr. Eamonn Hoxey, member of the Medical Technical Options Committee since 1996, is an Executive Director for Quality and Compliance for Johnson & Johnson. Dr Hoxey is a full time employee based in the UK. Johnson & Johnson has an interest in the topics of the Montreal Protocol as a manufacturer of healthcare products, including sterile products, and utilize in-house and external sterilization facilities that do not employ ODS. Dr Hoxey is chairman of the European standards committee on sterilization of medical devices. Dr Hoxey has no stock in companies involved in ODS, with the possible exception of stock held in portfolio accounts where he has no control over purchase or sale. Dr Hoxey’s partner has no interest in matters before the Protocol. Johnson & Johnson makes in-kind contributions of wage and miscellaneous expenses.

Javaid Khan, Pakistan (A5)
Prof. Javaid Khan, member of the Medical Technical Options Committee since 1999, is a Professor and Head Section of Pulmonology and Critical Care Medicine at the Aga Khan University, Karachi Pakistan. Dr Khan has attended Chest Conferences, such as ATS, sponsored by pharmaceutical companies. Dr Khan takes an active role in educating doctors and the public on asthma and COPD. Pharmaceutical companies have sponsored some of these meetings. Dr Khan has received honorarium from Pfizer company for his lectures to doctors on smoking cessation in 2007 in Pakistan. He is also a member of the Global Initiative for Asthma (GINA) assembly and Head of the Tobacco Prevention Section of the International Union Against Tuberculosis and Lung Diseases. In 2009 Prof. Javaid Khan responded to a request made by the Ministry of Environment Pakistan to provide information about the availability and cost of inhalers for Pakistan's essential use nomination.  He has no interest in the outcome of Pakistan's essential use nomination other than a physician's interest in ensuring MDIs remain available to patients at affordable prices. UNEP funds Dr Khan’s travel expenses to attend the meetings of MTOC.

Nasser Mazhari Motlagh, Iran (A5)
Dr. Nasser Mazhari Motlagh, member of the Medical Technical Option Committee since 2007, is a pharmacist at the Sina Darou Laboratories Company plc. Nasser Mazhari is a full time Quality Assurance Manager and Executive Deputy at the Sina Darou pharmaceutical and hygienic manufacturing plant, Tehran. Nasser Mazhari holds a doctorate in pharmacy and has more than 40 years experience in pharmaceutical industry (manufacturing), including more than 13 years in MDIs. The Sina Darou Laboratories Co. plc has an interest in the topics of the Montreal Protocol because it is manufacturing CFC MDIs and it is in the process of phasing out CFCs. Nasser Mazhari has no proprietary interest in alternatives or substitutes to ODSs, does not owns stock in companies producing ODS or alternatives or substitutes to ODS. His employer has an interest in the outcome of the Iran essential use nomination made in 2009. As a consequence, Nasser Mazhari abstained from participation in decision-making regarding Iran’s essential use nomination. Nasser Mazhari does consulting and working for Sina Darou to phase-out CFCs. Nasser Mazhari is a minor stockholder of Sina Darou Labs Co. plc. Nasser Mazhari's spouse has no interest in matters before the Protocol. Travel expenses of Nasser Mazhari to MTOC meetings are paid by UNEP’s Ozone Secretariat.

Hideo Mori, Japan (Non-A5)
Hideo Mori, member of the Medical Technical Options Committee since 1999, retired from the Regulatory Department at Otsuka Pharmaceutical, based in Tokushima Japan, and now works as an adviser at the same company. Otsuka Pharmaceutical accomplished the phase-out of CFC MDIs and manufactures CFC-free MDIs and DPIs. Mr Mori is the former chair and an adviser of the CFC Committee of the Federation of Pharmaceutical Manufacturers’ Association of Japan, which was organized to accomplish the phase-out of CFCs in MDIs and smooth transition to the alternatives. Mr. Mori does not own stocks in companies producing ODS, or alternatives or substitutes to ODS, does not have an interest in the outcome of essential use nominations. During 2008 and 2009 Mr Mori participated in regional UNEP workshops in South Asia, presenting on aspects of the Essential Use Nomination (EUN) process and assisting individual Article 5 Parties in the South Asia region in their EUN preparations. As a consequence, during the 2009 MTOC meeting Mr Mori abstained from participation in decisions regarding the EUNs from Bangladesh, China, India, Iran and Pakistan. The CFC Committee provides a grant for Mr Mori’s travel to attend MTOC and MOP/OEWG meetings. Otsuka Pharmaceutical provides other expenses for work relating to ozone layer protection.

Tunde Otulana, USA (Non-A5)
Dr Tunde Otulana, member of the Medical Technical Options Committee since 1995, is Senior Vice President and Chief Medical Officer at Aerovance Inc. Dr Otulana is a full time executive at Aerovance in Berkeley, California. Aerovance has an interest in the topics of the Montreal Protocol because it operates in the general field of respiratory diseases. Dr Otulana has no proprietary interest in alternatives or substitutes to ODS, does not own stock in companies producing ODS or alternatives or substitutes to ODS, does not have an interest in the outcome of essential use nomination, and does no consulting for organizations seeking to phase out ODS. Dr Otulana’s wife has no interest in matters before the Protocol. Dr Otulana’s travel to MTOC meetings is paid by Aerovance. 

Jose Pons Pons (co-chair), Venezuela (A5)
See TEAP disclosure

John Pritchard, UK (Non-A5)
Dr. John Pritchard, member of the Medical Technical Options Committee since 2006, is currently Strategic Technology Director for Pharmaceutical and Analytical R&D in AstraZeneca, having previously held a variety of roles within 3M, GlaxoSmithKline and AEA Technology (formerly UK Atomic Energy Authority). AstraZeneca has an interest in the topics of Montreal Protocol, as it is engaged in development, manufacturing and marketing of MDIs and DPIs in international markets. Dr. Pritchard has published extensively in the field of aerosol science and is a past President of The Aerosol Society, a past member of the UK Government Committee on the Medical Effects of Airborne Pollutants and has served as editor on a number of journals. Dr. Pritchard is also a minor shareholder in a range of companies, including GlaxoSmithKline that manufactures CFC MDIs and their alternatives. Participation in MTOC is supported by AstraZeneca, which develop and supply medicinal products, including inhalable drugs in a range of dosage forms, some of which are MDIs.

Rabbur Reza, Bangladesh (A5)
Rabbur Reza is a new member of the Medical Technical Option Committee since 2009. Rabbur Reza is the full time Director Marketing & Business Development at Beximco Pharmaceuticals Ltd, Bangladesh. Beximco Pharmaceuticals is the largest MDI manufacturer in Bangladesh and has an interest in the topics of Montreal Protocol, as it is engaged in development, manufacturing and marketing of MDIs in local and international markets. He has no proprietary interest in alternatives or substitutes to ODS, does not own stock in companies producing ODS or alternatives or substitutes to ODS; however, his employer has an interest in the outcome of the Bangladesh essential use nomination made in 2009. As a consequence, during the 2009 MTOC meeting Mr. Reza abstained from participation in decision-making regarding Bangladesh’s essential use nominations. Rabbur Reza has considerable experience in MDI product and business development and does consulting and working for Beximco Pharmaceuticals to phase out CFC based MDIs. Rabbur Reza’s spouse is a medical practitioner and has no interest in matters before the Protocol. UNEP’s Ozone Secretariat funds his travel expenses for participation on MTOC.

Raj Bright Singh, India (A5)
Dr Raj B Singh, member of the Medical Technical Options Committee since 2005, is a clinical respiratory physician engaged in private practice in Chennai, South India. Nearly 90 per cent of his work concerns clinical respiratory medicine, with out-patients at the Chest Centre and in-patient facilities at the Apollo Hospital, Chennai where he is a senior consultant. He is the founder of the Chest Foundation of India and its Managing Trustee. Dr Singh was a member of the Executive Committee of the Global Initiative for Asthma (GINA) from 2003 to 2007. He uses a portfolio management service that may buy shares of pharmaceutical companies from time to time. Attendance of the European Respiratory Society 2007 was funded by CIPLA. UNEP’s Ozone Secretariat funds his travel expenses for participation on MTOC.

Roland Stechert, Switzerland (Non-A5)
Dr. Roland Stechert, member of the Medical Technical Options Committee since 2000, is a Medical Director for Boehringer Ingelheim in Switzerland. Boehringer Ingelheim has an interest in the topics of Montreal Protocol, as it is engaged in development, manufacturing and marketing of MDIs and DPIs in international markets. As an expert of respiratory research Dr. Stechert was involved in the development of CFC-free MDIs with Boehringer Ingelheim. Dr Stechert headed the German regional International Pharmaceutical Aerosol Consortium (IPAC) Group until 2002. Since he took over his recent role in 2003 in Switzerland Dr Stechert is no longer a member of IPAC. Participation costs are all borne by the affiliate in Switzerland.

Helen Tope (co-chair), Australia (A5)
See TEAP disclosure

Ping Wang, China (A5)
Dr Wang Ping, MD, a member of the Medical Technical Options Committee since 2008, is the deputy secretary general of Chinese Pharmacopoeia Commission. Dr Wang Ping is a full time Chief pharmacist at the Chinese Pharmacopoeia Commission, Beijing, P.R.China. The Chinese Pharmacopoeia Commission has an interest in the topic of the Montreal Protocol because it making the standards for all the drugs sold in China, including for CFC MDIs for asthma and COPD. Dr Wang Ping has no proprietary interest in alternatives or substitutes to ODS, does not own stock in companies producing ODS or substitutes to ODS, does not have a financial interest in the outcome of essential use nominations, and does not consult for organizations seeking to phase out ODS. Dr Wang Ping's spouse also has no financial or other interest in matters before to the Montreal Protocol. UNEP’s Ozone Secretariat funds his travel expenses for participation on MTOC.

Adam Wanner, USA (Non-A5)
Dr. Adam Wanner, member of the Medical Technical Options Committee since 1995 has had a long-standing interest in aerosol therapy for obstructive lung disease, both as a researcher and clinician. On occasion, the American Lung Association and American Thoracic Society have sponsored his travel to MTOC meetings. Dr Wanner has received academic grants (unrelated to the CFC phase-out) from several pharmaceutical companies. Dr Wanner and his spouse have no financial interests relevant to his work on MTOC.

Kristine Whorlow, Australia (Non-A5)
Kristine Whorlow, member of the Medical Technical Options Committee since 2006, is the CEO of the National Asthma Council Australia. The National Asthma Council Australia has an interest in the Montreal Protocol because it led the phase-out of CFC-containing inhalers for respiratory disease in partnership with the Australian Department of the Environment in Australia. Ms Whorlow has no proprietary interest in alternatives or substitutes to ODS, does not own stock in companies producing ODS or alternatives or substitutes to ODS, does not have an interest in the outcome of essential use nominations. The National Asthma Council Australia receives funding from some pharmaceutical companies for projects in Australia and Asia Pacific not associated with the phase-out of ODS. At the invitation of UNEP ROAP, Ms Whorlow participated in the 2008 Langkawi regional workshop and the national transition awareness raising workshops in Maldives, Guyana and Nepal in 2008, and, in 2009, the national workshops in Iran and Pakistan. UNEP ROAP has contracted the National Asthma Council Australia to produce a package of resources on raising awareness of the transition to CFC free MDIs to assist countries preparing for phase-out. Ms Whorlow pays her own travel to MTOC meetings. Ms Whorlow’s partner has no interest in matters before the Protocol.

Ashley Woodcock (co-chair), UK (Non-A5)
See TEAP disclosure

You Yizhong, China (A5)
Dr. You Yizhong, member of the Medical Technical Options Committee since 1997, is a chief pharmacist and associate chief physician. Dr You has been devoted to promoting the wide use of inhalation therapy in China for 35 years and to phasing out CFCs from aerosols for 15 years. Dr You developed some anti-asthmatic drugs including MDI, tablet, syrup and suppository. Dr. You organized 14 aerosol conferences, seminars on the phase-out of CFCs from aerosols in China, including 4 special conferences on the phase-out of CFCs from pharmaceutical aerosols and MDIs. Dr You receives his salary from The First People’s Hospital of Changzhou and has no interest or economic relationship with pharmaceutical companies, and does not receive any fees for work associated with MTOC. UNEP's Ozone Secretariat funds his travel expenses to attend MTOC meetings.